Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 5
Submit an article Journal homepage
189
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study

Xiaoxue Zhua Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaView further author information
,
Min Wua Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaView further author information
,
Hong Wangb Jilin Medical Products Administration, Changchun, ChinaView further author information
,
Haijun Lic Medical Affairs, Guangdong Raynovent Biotech Co., Ltd, Shenzhen, ChinaView further author information
,
Junjie Linc Medical Affairs, Guangdong Raynovent Biotech Co., Ltd, Shenzhen, ChinaView further author information
,
Yun Pengd Medical Affairs, Guangdong Zhongsheng Pharmaceutical Co., Ltd, Dongguan, ChinaView further author information
,
Yue Hua Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaView further author information
,
Cuiyun Lia Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-6306-2394View further author information
ORCID Icon &
Yanhua Dinga Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaView further author information
 show all
Pages 579-589 | Received 30 Nov 2020, Accepted 05 Mar 2021, Published online: 25 Mar 2021

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (3)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.